ENANTA PHARMACEUTICALS, INC Income Taxes Paid
ENANTA PHARMACEUTICALS, INC (ENTA) reported Income Taxes Paid of $109.00 thousand for the 12-month period ending 2025-09-30, per its 10-K filed 2025-11-19.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:IncomeTaxesPaid · last filed 2025-11-19
- ENANTA PHARMACEUTICALS, INC income taxes paid for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid for the quarter ending 2020-06-30 was $55.00K, a 97.93% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid for the quarter ending 2019-09-30 was $57.00K, a 98.78% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid for the quarter ending 2019-06-30 was $2.66M, a 76.91% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC income taxes paid for fiscal 2025 was $109.00K, a 54.77% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC income taxes paid for fiscal 2024 was $241.00K, a 95.08% decline from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC income taxes paid for fiscal 2023 was $4.90M.
- ENANTA PHARMACEUTICALS, INC income taxes paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
| Period end | Income Taxes Paid 3 month | Income Taxes Paid 6 month | Income Taxes Paid 9 month | Income Taxes Paid 12 month |
|---|---|---|---|---|
| 2025-09-30 | $109.00K 10-K · filed 2025-11-19 | |||
| 2024-09-30 | $241.00K 10-K · filed 2025-11-19 | |||
| 2023-09-30 | $4.90M 10-K · filed 2025-11-19 | |||
| 2022-09-30 | $0.00 10-K · filed 2024-11-27 | |||
| 2021-09-30 | $32.00K 10-K · filed 2023-11-22 | |||
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $55.00K derived: sum of 2 quarters · filed 2022-11-23 | $105.00K 10-K · filed 2022-11-23 | |
| 2020-06-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | $105.00K 10-Q · filed 2020-08-10 | ||
| 2020-03-31 | $50.00K 10-Q · filed 2020-05-11 | |||
| 2019-09-30 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $2.72M derived: sum of 2 quarters · filed 2021-11-24 | $12.67M derived: sum of 3 quarters · filed 2021-11-24 | $12.67M 10-K · filed 2021-11-24 |
| 2019-06-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | $12.61M derived: sum of 2 quarters · filed 2020-08-10 | $12.62M 10-Q · filed 2020-08-10 | $17.30M derived: sum of 4 quarters · filed 2020-11-25 |
| 2019-03-31 | $9.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11 | $9.96M 10-Q · filed 2020-05-11 | $14.64M derived: sum of 3 quarters · filed 2020-11-25 | $26.16M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-12-31 | $5.00K 10-Q · filed 2020-02-10 | $4.69M derived: sum of 2 quarters · filed 2020-11-25 | $16.21M derived: sum of 3 quarters · filed 2020-11-25 | $26.08M derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-09-30 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | $16.20M derived: sum of 2 quarters · filed 2020-11-25 | $26.07M derived: sum of 3 quarters · filed 2020-11-25 | $26.09M 10-K · filed 2020-11-25 |
| 2018-06-30 | $11.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | $21.39M derived: sum of 2 quarters · filed 2019-08-09 | $21.40M 10-Q · filed 2019-08-09 | $21.96M derived: sum of 4 quarters · filed 2019-11-27 |
| 2018-03-31 | $9.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-10 | $9.88M 10-Q · filed 2019-05-10 | $10.44M derived: sum of 3 quarters · filed 2019-11-27 | $10.45M derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-12-31 | $13.00K 10-Q · filed 2019-02-08 | $574.00K derived: sum of 2 quarters · filed 2019-11-27 | $579.00K derived: sum of 3 quarters · filed 2019-11-27 | $583.00K derived: sum of 4 quarters · filed 2019-11-27 |
| 2017-09-30 | $561.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-11-27 | $566.00K derived: sum of 2 quarters · filed 2019-11-27 | $570.00K derived: sum of 3 quarters · filed 2019-11-27 | $1.59M 10-K · filed 2019-11-27 |
| 2017-06-30 | $5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-08-09 | $9.00K derived: sum of 2 quarters · filed 2018-08-09 | $1.03M 10-Q · filed 2018-08-09 | $4.53M derived: sum of 4 quarters · filed 2018-11-29 |
| 2017-03-31 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-05-10 | $1.02M 10-Q · filed 2018-05-10 | $4.52M derived: sum of 3 quarters · filed 2018-11-29 | $7.93M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-12-31 | $1.02M 10-Q · filed 2018-02-09 | $4.52M derived: sum of 2 quarters · filed 2018-11-29 | $7.92M derived: sum of 3 quarters · filed 2018-11-29 | $7.93M derived: sum of 4 quarters · filed 2018-11-29 |
| 2016-09-30 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-29 | $6.91M derived: sum of 2 quarters · filed 2018-11-29 | $6.91M derived: sum of 3 quarters · filed 2018-11-29 | $12.62M 10-K · filed 2018-11-29 |
| 2016-06-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-09 | $3.41M derived: sum of 2 quarters · filed 2017-08-09 | $9.12M 10-Q · filed 2017-08-09 | |
| 2016-03-31 | $4.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-10 | $5.71M 10-Q · filed 2017-05-10 | ||
| 2015-12-31 | $5.71M 10-Q · filed 2017-02-09 | |||
| 2015-09-30 | $40.07M 10-K · filed 2017-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |